Correlation Between Iovance Biotherapeutics and LMF Acquisition

Can any of the company-specific risk be diversified away by investing in both Iovance Biotherapeutics and LMF Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iovance Biotherapeutics and LMF Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Iovance Biotherapeutics and LMF Acquisition Opportunities, you can compare the effects of market volatilities on Iovance Biotherapeutics and LMF Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iovance Biotherapeutics with a short position of LMF Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iovance Biotherapeutics and LMF Acquisition.

Diversification Opportunities for Iovance Biotherapeutics and LMF Acquisition

0.36

Correlation Coefficient

Iovance Biotherapeutics  LMF Acquisition

Weak diversification

The 3 months correlation between Iovance and LMF is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Iovance Biotherapeutics and LMF Acquisition Opportunities in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on LMF Acquisition Oppo and Iovance Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iovance Biotherapeutics are associated (or correlated) with LMF Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of LMF Acquisition Oppo has no effect on the direction of Iovance Biotherapeutics i.e., Iovance Biotherapeutics and LMF Acquisition go up and down completely randomly.

Pair Corralation between Iovance Biotherapeutics and LMF Acquisition

Given the investment horizon of 90 days Iovance Biotherapeutics is expected to generate 0.65 times more return on investment than LMF Acquisition. However, Iovance Biotherapeutics is 1.54 times less risky than LMF Acquisition. It trades about -0.04 of its potential returns per unit of risk. LMF Acquisition Opportunities is currently generating about -0.05 per unit of risk. If you would invest  818.00  in Iovance Biotherapeutics on September 16, 2024 and sell it today you would lose (35.00) from holding Iovance Biotherapeutics or give up 4.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Iovance Biotherapeutics  vs.  LMF Acquisition Opportunities

Iovance Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

LMF Acquisition Oppo

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days LMF Acquisition Opportunities has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Iovance Biotherapeutics and LMF Acquisition

The main advantage of trading using opposite Iovance Biotherapeutics and LMF Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iovance Biotherapeutics position performs unexpectedly, LMF Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LMF Acquisition will offset losses from the drop in LMF Acquisition's long position.

The idea behind Iovance Biotherapeutics and LMF Acquisition Opportunities pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.